Esomeprazole-Based 1-Week Triple Therapy Directed by Susceptibility Testing for Eradication of Helicobacter pylori Infection in Children

    loading  Checking for direct PDF access through Ovid



Poor compliance to therapy and antibiotic resistance are the main causes for failure of anti-Helicobacter pylori therapy.


To evaluate the effectiveness of esomeprazole-based triple therapy directed by susceptibility testing.


Symptomatic children with H. pylori infection, who underwent successful susceptibility testing and were colonized by no double-resistant strain, received 1-week triple therapy with esomeprazole, amoxicillin and either clarithromycin or metronidazole. Success of eradication was investigated by 13C-urea breath test.


Fifty-eight children (median age, 11.4 years; range, 2.2-17.7 years; 81% immigrants) were included. Helicobacter pylori was resistant to clarithromycin in 5 (9%) and to metronidazole in 9 children (16%). Eradication was successful in 49 (92%) of 53 children receiving esomeprazole, amoxicillin and clarithromycin and in all 5 children treated with metronidazole instead of clarithromycin, resulting in an eradication rate of 93% (95% confidence interval, 83%-98%, intention-to-treat analysis). All 4 treatment failures occurred in immigrants with language problems; 2 of them were obviously noncompliant.


Esomeprazole-based 1-week triple therapy directed by susceptibility testing is highly effective for eradication of H. pylori infection in children.

Related Topics

    loading  Loading Related Articles